
ZGNX
Healthcare · Pharmaceuticals · $1.50B market cap
Latest report
Time not confirmed
The next earnings date isn’t on the calendar yet.
Analyst consensus
Fiscal period ending Mar 31, 2022
EPS trend, 90 days to now · -4.7% over 90 days · 30-day revisions 1 up, 0 down
Beat estimates in 1 of the last 4 reported quarters.
EPS surprise versus the estimate at the time of the report.
| Date | Session | Estimate | Actual | Surprise |
|---|---|---|---|---|
| Feb 28, 2022 | Time not confirmed | -0.88 | -0.98 | -11.4% |
| Nov 4, 2021 | After the close | -0.98 | -1.04 | -6.4% |
| Aug 5, 2021 | After the close | -0.93 | -1.05 | -12.7% |
| May 6, 2021 | After the close | -1.02 | -1.00 | +1.9% |
| Feb 25, 2021 | After the close | -1.01 | -1.26 | -25.0% |
| Nov 9, 2020 | After the close | -1.00 | -1.08 | -8.2% |
| Aug 6, 2020 | After the close | -0.99 | -0.96 | +2.9% |
| May 5, 2020 | After the close | -1.08 | -0.54 | +50.1% |
| Mar 2, 2020 | After the close | -1.06 | -1.26 | -18.9% |
| Nov 7, 2019 | After the close | -1.02 | -6.75 | -561.1% |
| Aug 6, 2019 | After the close | -0.78 | -0.89 | -13.8% |
| May 8, 2019 | After the close | -0.86 | -0.83 | +3.1% |
| Feb 28, 2019 | After the close | -1.01 |
Zogenix, Inc., a biopharmaceutical company, develops and commercializes therapies to transform the lives of patients and their families living with rare diseases in the United States. The company's lead product candidate is the Fintepla, a low-dose fenfluramine, which is in Phase III clinical trials for the treatment of seizures associated with Dravet syndrome, as well as to treat seizures associated with…
| -0.53 |
| +47.5% |
| Nov 8, 2018 | After the close | -0.89 | -1.08 | -21.0% |
| Aug 6, 2018 | After the close | -0.89 | -0.83 | +7.0% |
| May 9, 2018 | After the close | -0.74 | -0.87 | -17.9% |
| Mar 6, 2018 | After the close | -0.89 | -1.17 | -31.0% |